Acquired donor center and laboratory enables BioIVT to ship high quality blood products and blood-derived immune cells efficiently to researchers throughout Europe
WESTBURY, NY, US - Oct 8, 2018 - BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Clinical Trials Laboratory Services (CTLS), a donor center and laboratory based in London, UK. CTLS provides dedicated high-quality serum, plasma and blood collection services. It also offers full-service cell processing capabilities on site.
We are delighted that CTLS is now part of BioIVT, said BioIVT CEO Jeff Gatz. This is BioIVTs first donor center in Europe and we are excited to be able to address our clients needs by offering fresh blood and blood-derived products. CTLS expands our immune cell offering, which is one of the fastest growing segments of our company. This acquisition increases our capabilities and improves the efficiency with which we can deliver high quality biospecimens to our clients in Europe.
All CTLS employees will join BioIVT and CTLS London headquarters will become the primary site in Europe for donor collections.
This acquisition increases BioIVTs capacity to produce fresh peripheral blood mononuclear cells and other immune cell subsets such as natural killer cells, B cells, and T cells to meet clients research needs. It also enables BioIVT to ship fresh blood and blood-derived products to researchers anywhere in Europe within 24 hours.
CTLS is an excellent addition to BioIVT, said UK General Manager Kelly Sapsford. The companies complement each other, with CTLS employees sharing our strong work ethic, commitment to supplying the highest quality biospecimens, and unremitting desire to advance medical research across Europe.
Underscoring CTLS commitment to excellence, its staff members are registered with the UK-based Health & Care Professions Council.
European researchers will be able to rely on BioIVT to provide a consistent supply of fresh blood and blood products for their studies. They will no longer need to contend with variable availability from hospital sources, Ms. Sapsford added.
We are excited to be joining BioIVT and expanding the breadth and depth of products and services that we can offer to our customers, said CTLS Laboratory Director Dr. Rukhsana Ahsan. We are looking forward to beginning this next phase of our companys growth and development.
Financial details about this transaction were not disclosed.
About BioIVT
BioIVT, formerly BioreclamationIVT, is a leading global provider of research models and value-added research services for drug discovery and development. We specialize in control and disease-state biospecimens including human and animal tissues, cell products, blood and other biofluids. Our unmatched portfolio of clinical specimens directly supports precision medicine research and the effort to improve patient outcomes by coupling comprehensive clinical data with donor samples. Our PHASEZERO® Research Services team works collaboratively with clients to provide target and biomarker validation, phenotypic assays to characterize novel therapeutics, clinical assay development and
in vitro
hepatic modeling solutions. And as the premier supplier of ADME-toxicology model systems, including hepatocytes and subcellular fractions, BioIVT enables scientists to better understand the pharmacokinetics and drug metabolism of newly-discovered compounds and their effects on disease processes. By combining our technical expertise, exceptional customer service, and unparalleled access to biological specimens, BioIVT serves the research community as a trusted partner in elevating science. For more information, please visit
www.bioivt.com
or follow the company on Twitter
@BioIVT
.